Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (315)	12/23/1997 10:27:00 AM
From: Roader	Respond to of 756

RPT: Ivax Corp - Buyback -2: Co. May Also Sell Put Options Dow Jones News Service via Dow Jones MIAMI (Dow Jones)--Ivax Corp. (IVX) received approval to repurchase up to 5 million common shares. In a press release Tuesday, the company said it will buy the shares from time to time. Under the plan, Ivax's managment may also sell put options. Those transactions may be done privately or on the open market. For the third quarter ended Sept. 30, the company had an average 121.5 million shares outstanding. Ivax is a holding company with operating units that research and develop drugs.

To: flickerful who wrote (315)	12/23/1997 10:28:00 AM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

Randy, the IVX news is all good now; everything points to a bottom: 1) rights plan is bullish; 2) insider buying is very bullish; 3) share repurchase is bullish (even though it's only 4+%); 4) approvals of clozapine & verapamil; 5) volume is picking up a little. IVX will begin to appear on more radar screens as a beaten down bargain. A significant news event like Paxene being approved in Timbuctu will send the shares nicely higher. Good luck, Jackson

To: flickerful who wrote (315)	12/23/1997 10:05:00 PM
From: harkenman	Read Replies (1) \| Respond to of 756

Ivax Corp. Clears Buyback Of Up To 5M Common Shares Dow Jones Newswires MIAMI -- Ivax Corp. (IVX) received approval to repurchase up to 5 million common shares. In a press release Tuesday, the company said it will buy the shares from time to time. Under the plan, Ivax's managment may also sell put options. Those transactions may be done privately or on the open market. For the third quarter ended Sept. 30, the company had an average 121.5 million shares outstanding. Ivax is a holding company with operating units that research and develop drugs.